Local Institution
Montpellier 34298
0 studies enrolling now · 30 studies all time
What they study most
Acute Coronary Syndrome, Cancer, Deep-Vein Thrombosis, Hepatitis C, Hepatitis C Virus, Hepatitis C Virus (HCV), Hepatitis C Virus Infection, Hepatitis C, Genotype 1, Immunosuppression in Solid Organ Transplant, Liver Cancer, Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction, Lymphoma
Studies at this site
- Pan Tumor Rollover Study — Recruiting now
- Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis — Completed
- Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) — Completed
- Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia — Completed
- Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial — Completed
- Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment — Completed
- Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis — Completed
- A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia — Completed
- Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis — Completed
- Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials — Completed
- An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy — Completed
- Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus — Completed
- Phase III Acute Coronary Syndrome — Stopped early
- Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis — Completed
- Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection — Completed
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
- Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients — Completed
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin — Completed
- Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) — Completed
- Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis — Completed
- Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin — Completed
- Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial — Completed
- Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone — Completed
- Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer — Completed
- Belatacept in Liver Transplant Recipients — Stopped early
- Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis — Stopped early
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy — Completed
- Remission and Joint Damage Progression in Early Rheumatoid Arthritis — Completed
- Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study — Completed